pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Bispecific Antibody · news · pharmadog
← back to Bispecific Antibody
News · Bispecific Antibody
285
stories
18d
Novo’s CEO still looking for deals to ‘close some of the gaps,’ as misfires hit profits
fiercebiotech
19d
T-Therapeutics raises $133M series B for bispecific pipeline with Big Pharma backers in tow
fiercebiotech
20d
Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict
biospace
23d
AstraZeneca employs $1.5B cost savings to reinvest back into growth
biospace
23d
Bambusa shoots past IPO targets as Aspen trims offering
fiercebiotech
23d
Molecular Partners to lay off up to 44% of workforce in radiotherapy pivot
fiercebiotech
24d
Dren Bio lands $350M to push rare blood cancer therapy toward market
biospace
24d
Genmab soars to record highs after cancer drug succeeds in key trial
biopharma dive
24d
Merck outlines 2027 as ‘another year of investment’ despite recent clinical wins
fiercebiotech
25d
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
biospace
25d
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
biospace
25d
Astellas bets up to $1.34B for option to advance Audax immuno-oncology asset
biospace
25d
Genmab's $8B Merus bet delivers as bispecific combo halves risk of death in phase 3
fiercebiotech
25d
GSK predicts ‘some limited impact’ to UK roles as restructuring rolls on
fiercebiotech
26d
Parkinson’s-focused Aspen and bispecific biotech Bambusa both shoot for $134M IPOs
fiercebiotech
27d
ESMO 2026: Analysts warm to Merck, Moderna’s cancer vaccine after frustrating data leak
biospace
27d
ESMO 2026: Amgen’s Imdelltra slashes death risk by nearly 60% in small cell lung cancer
biospace
27d
Genmab’s ADC beats survival expectations in Phase 3 ovarian cancer trial
biospace
27d
Novel protein and peptide therapeutics
biopharma dive
27d
BioNTech sees ‘limited’ benefit to ADC after phase 3 reveals modest efficacy, ILD cases
fiercebiotech
28d
#ESMO26: Akeso details ivonescimab's biliary cancer success, drawing Keytruda comparisons
endpoints
28d
ESMO: BMS’ Massacesi hails ‘very promising’ data for BioNTech-partnered PD-L1xVEGF-A drug
fiercebiotech
28d
ESMO: Why Incyte sees itself ‘neck and neck’ with RevMed in KRAS G12D pancreatic cancer race
fiercebiotech
Oct 23, 26
ESMO 2026: Marengo's bispecific antibody shrinks 8 tumor types in Phase 2
biospace
Oct 23, 26
Roche bets up to $813M on Zymeworks’ lung cancer trispecific T cell engager
biospace
Oct 23, 26
ESMO: Takeda’s $1.2B bet on Innovent ‘absolutely’ pays off with details of ADC’s phase 3 win
fiercebiotech
Oct 23, 26
Roche pays Zymeworks $55M for trispecific challenger to Amgen’s Imdelltra
fiercebiotech
Oct 22, 26
Treasury sweeps biotech into proposed COINS Act restrictions, but spares Big Pharma’s China licensing deals
fiercebiotech
Oct 22, 26
Biotech notches 31 IPOs already this year, with 4 more joining queue
biospace
Oct 22, 26
ESMO: Boehringer builds case for late-phase rival to Amgen’s Imdelltra
fiercebiotech
← prev
page 2 of 10
next →